Peroxisome proliferator-activated receptor γ agonist reduces the severity of post-ERCP pancreatitis in rats

• Published in: World journal of gastroenterology : WJG 2006-10, Vol.12 (40), p.6458-6463
• Main Authors: Folch-Puy, Emma, Granell, Susana, Iovanna, Juan L, Barthet, Marc, Closa, Daniel
• Format: Article
• Language: English
• Subjects: Acute Disease; Animals; Basic Research; Cholangiopancreatography, Endoscopic Retrograde - adverse effects; Contrast Media - adverse effects; Gene Expression Regulation - drug effects; Gene Expression Regulation, Enzymologic - drug effects; Lipase - blood; Liver - enzymology; Male; NF-kappa B - genetics; NF-kappa B - metabolism; Nitric Oxide Synthase Type II - genetics; Nitric Oxide Synthase Type II - metabolism; Pancreatitis - chemically induced; Pancreatitis - drug therapy; Peroxidase - genetics; Peroxidase - metabolism; PPAR gamma - agonists; PPAR gamma - genetics; PPAR gamma - metabolism; Rats; Rats, Wistar; Rosiglitazone; Severity of Illness Index; Thiazolidinediones - pharmacology; Thiazolidinediones - therapeutic use; 胰腺炎; 过氧物酶体
• ISSN: 1007-9327; 2219-2840
• DOI: 10.3748/wjg.v12.i40.6458

AIM： To determine the effects of prophylactic peroxisome proliferator-activated receptor （PPARy） agonist administration in an experimental model of post-endoscopic retrograde cholangiopancreatography （post-ERCP） acute pancreatitis. METHODS： Post-ERCP pancreatitis was induced in male Wistar rats by infusion of contrast medium into the pancreatic duct. In additional group, rosiglitazone, a PPARγ agonist, was administered 1 h before infusion of contrast medium. Plasma and pancreas samples were obtained 6 h after the infusion. RESULTS： Infusion of contrast medium into the pancreatic duct resulted in an inflammatory process characterized by increased lipase levels in plasma, and edema and myeloperoxidase activity （MPO） in pancreas. This result correlated with the activation of nuclear factor κB （NFκB） and the inducible NO synthase （iNOS） expression in pancreatic cells. Rosiglitazone reduced the increase in lipase and the level of edema and the increase in myeloperoxidase as well as the activation of NFκB and iNOS expression. CONCLUSION： A single oral dose of rosiglitazone, given 1 h before post-ERCP pancreatitis induction is effective in reducing the severity of the subsequent inflammatory process. The protective effect of rosiglitazone was associated with NFκB inhibition and the blockage of leukocyte infiltration in pancreas.